Information Provided By: 
Fly News Breaks for June 30, 2017
BIOS
Jun 30, 2017 | 09:06 EDT
Craig-Hallum analyst Kevin Ellich noted that BioScrip's debt refinancing deal included a private placement of shares and in-the-money warrants, which was "was unexpected and disappointing." However, he views the refinancing as an incremental positive as it extends debt maturities and gives management more time to focus on their turnaround efforts. Ellich keeps a Buy rating on BioScrip shares and raised his price target to $3.50 from $2.50.
News For BIOS From the Last 2 Days
There are no results for your query BIOS
